Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burlulipase in EPI due to Cystic Fibrosis
NCT01710644Phase 2Completed
- Sponsor
- Nordmark Pharma
- Start
- May 2013
- Primary completion
- Jul 2014
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of burlulipase in exocrine pancreatic insufficiency (EPI), sponsored by Nordmark Pharma. Started May 2013; status: completed.
02
Drugs
burlulipase
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT01710644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01710644.